1. Show article details.

    Devon Energy, Eli Lilly Are CNBC 'Fast Money' Mentions, With Kevin O'Leary Selling These 7 Stocks

    Benzinga – 2:02 PM ET 08/19/2022

    CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned.

  2. Show article details.

    Eli Lilly Whale Trades For August 18

    Benzinga – 12:52 PM ET 08/18/2022

      A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly we detected 15 strange trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.

  3. Show article details.

    Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years

    Benzinga – 2:03 PM ET 08/16/2022

      Eli Lilly has outperformed the market over the past 10 years by 10.36% on an annualized basis producing an average annual return of 22.1%. Currently, Eli Lilly has a market capitalization of $295.32 billion. Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $7,342.23 today based on a price of $310.81 for LLY at the time of writing.

  4. Show article details.

    Landmark Drug Pricing Reform Bill Passes Congress House

    Benzinga – 7:48 AM ET 08/15/2022

    Landmark Drug Pricing Reform Bill Passes Congress House

  5. Show article details.

    Weekend Stock Spotlight: Affirm, SoftBank And How Trump Documents Seizure May Impact Midterms

    Benzinga – 4:50 PM ET 08/13/2022

    Benzinga reviews this weekend's top stories covered by leading media outlets, here are the articles investors need to read. In Barron's "At Last, Weight-Loss Drugs That Actually Work. "The SoftBank Experiment Has Failed.

  6. Show article details.

    Raymond James Bullish On This Penny Stock's Reprioritized Pipeline

    Benzinga – 2:05 PM ET 08/12/2022

    Raymond James Bullish On This Penny Stock's Reprioritized Pipeline

  7. Show article details.

    Eli Lilly's Return On Capital Employed Insights

    Benzinga – 10:04 AM ET 08/12/2022

      According to Benzinga Pro, during Q2, Eli Lilly earned $952.50 million, a 49.94% increase from the preceding quarter. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

  8. Show article details.

    Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

    Benzinga – 6:07 PM ET 08/11/2022

    Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

  9. Show article details.

    This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing

    Benzinga – 2:48 PM ET 08/11/2022

    This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing

  10. Show article details.

    Eli Lilly Whale Trades For August 11

    Benzinga – 1:03 PM ET 08/11/2022

      Someone with a lot of money to spend has taken a bearish stance on Eli Lilly. And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know. So how do we know what this whale just did?

  11. Show article details.

    ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off

    Benzinga – 10:52 AM ET 08/11/2022

    ALX Oncology Holdings has initiated a Phase 2 investigator-sponsored study of evorpacept in combination with Eli Lilly's ERBITUX and Merck's KEYTRUDA in patients with refractory microsatellite stable metastatic colorectal cancer. Eli Lilly and Merck will provide ERBITUX, an anti-EGFR antibody and KEYTRUDA, an anti-PD-1 therapy to support this study.

  12. Show article details.

    BRIEF-Lilly Announces Leadership Transition In Human Resources And New Chief Commercial Officer For Loxo@Lilly

    Reuters – 9:49 AM ET 08/11/2022

    Eli Lilly and Co (LLY): * LILLY ANNOUNCES LEADERSHIP TRANSITION IN HUMAN RESOURCES AND NEW CHIEF COMMERCIAL OFFICER FOR LOXO@LILLY. * ELI LILLY (LLY) - STEPHEN FRY TO RETIRE AT END OF 2022 Source text for Eikon: Further company coverage:

  13. Show article details.

    Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly

    PR Newswire – 8:30 AM ET 08/11/2022

    - Stephen Fry to retire at the end of 2022 - Eric Dozier named Senior Vice President, Human Resources and Diversity - Winselow Tucker to join Lilly as Senior Vice President and Chief Commercial Officer for Loxo@Lilly INDIANAPOLIS, Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hi...

  14. Show article details.

    BRIEF-Lilly's Taltz Now Available In New, Citrate-Free Formulation To Reduce Injection Site Pain For Improved Patient Experience

    Reuters – 7:44 AM ET 08/08/2022

    Eli Lilly and Co (LLY): * LILLY'S TALTZ® NOW AVAILABLE IN NEW, CITRATE-FREE FORMULATION TO REDUCE INJECTION SITE PAIN FOR IMPROVED PATIENT EXPERIENCE Source text for Eikon: Further company coverage:

  15. Show article details.

    Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience

    PR Newswire – 6:45 AM ET 08/08/2022

    Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz INDIANAPOLIS, Aug. 8, 2022 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today the availability of a new, citrate-free formulation of Taltz® injection 80 mg/mL.

  16. Show article details.

    What Are Whales Doing With Eli Lilly

    Benzinga – 2:11 PM ET 08/05/2022

    A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and 81% with bearish.

  17. Show article details.

    Looking Into Eli Lilly's Recent Short Interest

    Benzinga – 12:09 PM ET 08/05/2022

    Eli Lilly's short percent of float has risen 11.29% since its last report. Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock.

  18. Show article details.

    Market Volatility Eases Further As Nasdaq Reaches New Three-Month High

    Benzinga – 6:24 AM ET 08/05/2022

    The Nasdaq index jumped to a fresh three-month high on Thursday ahead of the much-awaited jobs report for the month of July. However, U.S. stocks closed mixed on Thursday as energy stocks, including, Exxon Mobil Corp and Chevron Corporation weighed on the S&P 500 index in the previous session.

  19. Show article details.

    U.S. Job Growth Might Slow To This Level In July, Here Are The Major Macro Issues For Friday

    Benzinga – 4:23 AM ET 08/05/2022

    U.S. stocks closed mixed on Thursday as Eli Lilly And Co reported downbeat results for its second quarter and lowered its FY22 guidance. Below is a look at the major economic reports scheduled for release today. Federal Reserve Bank of Richmond President Thomas Barkin is set to speak at 8:00 a.m. ET.

  20. Show article details.

    US STOCKS-Wall Street ends mixed as investors eye jobs data

    Reuters – 4:25 PM ET 08/04/2022

    * Indexes: Dow slips 0.26%, S&P off 0.08%, Nasdaq up 0.41% * Energy stocks down as oil slumps to pre-Ukraine war level. * Eyes on Friday's nonfarm payrolls report. By Sruthi Shankar and Medha Singh.

Page:

Today's and Upcoming Events

  • Nov
    01

    LLY to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    12

    LLY ex-Dividend for $0.98 on 08/12/2022

    • Announce Date: 06/27/2022
    • Record Date: 08/15/2022
    • Pay Date: 09/09/2022
  • Aug
    04

    LLY announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.